Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/455)
-
Publication number: 20110002918Abstract: Treatment protocols for severe psoriasis include administering biologics, stopping all administration of the biologics after the severity of the psoriasis has reduced and has reached an equilibrium, mildness and/or a tolerable state of remission, and administering UV phototherapy. The biologics may include, for example, the biologics found in Amevive®, Enbrel®, Humira®, Raptiva®, and Remicade® and/or alefacept, etanercept, adalimumab, efalizumab, infliximab, and ustekinumab. The UV phototherapy may be repeated, for example daily, weekly, monthly, yearly, to keep the psoriasis in a mild state or in a tolerable state of substantial remission. Parameters for administering UV phototherapy may be determined based on skin tone, Fitzpatrick skin phenotype, the severity of the psoriasis, the area of exposure, and/or the MED.Type: ApplicationFiled: March 5, 2010Publication date: January 6, 2011Applicant: PHOTOMEDEXInventor: Jeffrey I. Levatter
-
Patent number: 7863322Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: March 2, 2004Date of Patent: January 4, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Patent number: 7863321Abstract: The present invention relates to synergistic combinations of the compound 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from anthracyclines and topisomerase II inhibitors, which have anti-tumor activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from etoposide, and doxorubicin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.Type: GrantFiled: July 30, 2007Date of Patent: January 4, 2011Assignee: Cancer Research Technology LimitedInventors: William R. Wilson, Bronwyn G. Siim
-
Publication number: 20100330009Abstract: The present invention relates to derivatives of the 1H-pyrano[4,3-b]benzofuran-1-one structure and their nitrogen analogues which possess powerful antioxidant properties combined with a highly effective UV absorbing functionality in one molecule. These compounds are especially useful in cosmetical and dermatological formulations.Type: ApplicationFiled: February 29, 2008Publication date: December 30, 2010Applicant: CIBA CORPORATIONInventors: Barbara Wagner, Sebastien Mongiat, Bernd Herzog, Werner Baschong, Andreas Buthe, Reinhold Ohrlein
-
TETRACYCLIC DIPYRANO-COUMARIN COMPOUNDS WITH ANTI-HIV AND ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITIES
Publication number: 20100324067Abstract: The present invention relates to tetracyclodipyrano-coumarin compounds of general formula (I), wherein the substituents are defined herein. These compounds exihibit dual biological activities of anti human immunodeficiency virus type 1 (HIV-1) infection and anti-Mycobacterium Tuberculosis (TB) infection.Type: ApplicationFiled: November 5, 2007Publication date: December 23, 2010Inventors: Gang Liu, Hai Xue, Tao Ma, Ziwei Chen, Lin Wang -
Publication number: 20100324131Abstract: The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.Type: ApplicationFiled: August 6, 2010Publication date: December 23, 2010Inventors: Cécile Béguin, William A. Carlezon, Bruce M. Cohen, Minsheng He, David Yue-Wei Lee, Michele R. Richards, Lee-Yuan Liu Chen
-
Publication number: 20100311826Abstract: The present invention relates to xanthone compounds isolated from the plant Psorospermum molluscum Hochr. (Clusiaceae), a Madagascar plant, which are potent cytotoxic agents.Type: ApplicationFiled: September 11, 2008Publication date: December 9, 2010Inventors: John E. Leet, Craig R. Fairchild, Stephen W. Mamber, Xiaohong Liu
-
Patent number: 7846965Abstract: A compound is described. In particular, a non-steroidal sulphamate compound is described. The compound is suitable for use as an inhibitor of oestrone sulphatase. The compound is of general Formula (A), wherein R1-R6 are independently selected from H, halo, hydroxy, sulphamate, alkyl and substituted variants or salts thereof; but wherein at least one of R1-R6 is a sulphamate group; and wherein X is any one of S, NH, a substituted N, CH2, or a substituted C.Type: GrantFiled: February 26, 2007Date of Patent: December 7, 2010Assignee: Sterix LimitedInventors: Michael John Reed, Barry Victor Lloyd Potter
-
Patent number: 7842721Abstract: A pharmaceutical composition having a cytotoxic effect to a cancer cell is provided. The pharmaceutical composition includes a flavonoid compound having a formula as wherein B ring is a 4-oxo-cyclohexa-2,5-dienyl group, and any one of R1-R12 is one selected from a group consisting of hydrogen group, hydroxyl group, C1-C20 alkyl group, C1-C20 ether group, C1-C20 ester group, carboxyl group, halogen and sugar. The flavonoid compound is obtained from a chemical method being one of a total synthesis method and a semi-synthesis method.Type: GrantFiled: August 24, 2007Date of Patent: November 30, 2010Assignee: Kaohsiung Medical UniversityInventors: An-Shen Lin, Yang-Chang Wu, Kuo-Hsiung Lee, Fang-Rong Chang
-
Publication number: 20100298423Abstract: Pharmaceutical, cosmetic, nutraceutical and dietary compositions derived from Garcinia mangostana are rich in ?-mangostin and other demethylated xanthones. These compositions exhibit potent antioxidative activity and reduce inflammation. These compositions may be used in a method of treating TNF-?, and aP2 mediated disorders. The compositions are prepared by subjecting a hydroalcoholic extract of fruit pericarp (fruit hull) of Garcinia mangostana, wherein said hydroalcoholic extract comprises predominantly ?-mangostin, to demethylation in the presence of a Lewis acid, an organic base and a catalyst.Type: ApplicationFiled: January 21, 2008Publication date: November 25, 2010Applicant: LAILA NUTRACEUTICALSInventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Trimurtulu Golakoti, Kiran Bhupathiraju
-
Publication number: 20100297112Abstract: The present invention relates to combinations of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vascular endothelial growth factor binders, in particular the monoclonal antibody Avastin™ (bevacizumab). More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical formulations containing such combinations.Type: ApplicationFiled: August 25, 2006Publication date: November 25, 2010Inventors: Colin Green, Lloyd Kelland, Gail Rowlinson-Bruza
-
Publication number: 20100298422Abstract: Novel polyspirane compounds used in the treatment of diseases involving parasites that belong to the phylum of apicomplexae, and a method for preparing the same.Type: ApplicationFiled: October 2, 2008Publication date: November 25, 2010Applicants: UNIVERSITE JOSEPH FOURIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Yung-Sing Wong, Marine Aimee Peuchmaur, Eric Marechal, Cyrille Botte, Henri Joseph Vial, Nadia Saidani
-
Publication number: 20100297215Abstract: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.Type: ApplicationFiled: May 11, 2009Publication date: November 25, 2010Inventors: William E. Fahl, Nalini Raghavachari, Ming Zhu, John A. Kink
-
Publication number: 20100286254Abstract: The present invention relates to pharmaceutically stable crystalline forms of (5,6-Dimethyl-9-oxo-9H-xanthene-4-yl)acetic acid (DMXAA) sodium salt, processes for preparing those stable crystalline forms; pharmaceutical compositions comprising at least one of those crystalline forms in solid form or in dissolved form and a pharmaceutically acceptable carrier. Disclosed are methods of using those pharmaceutical compositions to treat tumours, optionally in combination with other active pharmaceutical agents.Type: ApplicationFiled: October 21, 2008Publication date: November 11, 2010Applicant: ANTISOMA RESEARCH LIMITEDInventors: Fritz Blatter, Rolf Hilfiker
-
Publication number: 20100279964Abstract: The present invention relates to methods of using 3?,4?-aromatic acyloxy substituted 7,8-pyranocoumarins compounds in reversing P-glycoprotein overexpression mediated multidrug resistance in cancer cells including uses in treating cancers.Type: ApplicationFiled: July 16, 2010Publication date: November 4, 2010Inventors: Wangfun Fong, Xiaoling Shen, Guangying Chen, Guoyuan Zhu, Chikeung Wan, Kaiwing Tse
-
Patent number: 7824745Abstract: The present invention relates to benzochromene derivatives of the formula I where the various parameters have the meaning indicated in the text, and to liquid-crystal media which comprise these compounds, and to the use of the media in electro-optical displays, in particular in VAN-LCDs, and to the use of the compounds and physiologically acceptable derivatives thereof as therapeutic active ingredients.Type: GrantFiled: December 5, 2006Date of Patent: November 2, 2010Assignee: Merck Patent GmbHInventors: Andreas Taugerbeck, Melanie Klasen-Memmer
-
Patent number: 7825157Abstract: There are provided methods and compositions for improving the aesthetic appearance of akin, treating rosacea and/or telangiectasia, and treating the signs of dermatological aging. The method is directed to topically applying to an affected area an effective amount of mangostin, an analog thereof, or a combination thereof.Type: GrantFiled: December 30, 2004Date of Patent: November 2, 2010Assignee: Avon Products, Inc.Inventor: Dmitri Ptchelintsev
-
Publication number: 20100272717Abstract: The invention relates to a combination comprising vascular disrupting agent (VDA), such as 5,6-dimethylxanthenone-4-acetic acid or a pharmaceutically acceptable salt, ester or prodrug thereof; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.Type: ApplicationFiled: December 4, 2008Publication date: October 28, 2010Applicant: NOVARTIS AGInventors: Dean Brent Evans, Christian J. Jacques
-
Publication number: 20100266676Abstract: The invention relates to nanocapsules with a liquid lipidic core and a solid lipidic shell, the lipidic core being loaded with at least one water-soluble or water-dispersible ingredient, said ingredient being present in the form of a reverse micellar system.Type: ApplicationFiled: June 11, 2008Publication date: October 21, 2010Applicant: UNIVERSITE D' ANGERSInventors: Patrick Saulnier, Jean-Pierre Benoit, Nicolas Anton
-
Patent number: 7812051Abstract: The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified ?-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as ?-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues.Type: GrantFiled: August 11, 2005Date of Patent: October 12, 2010Assignee: ArQule, Inc.Inventors: Mark A. Ashwell, Chiang J. Li, Manish Tandon, Yanbin Liu, Jean-Marc LaPierre, Zhiwei Jiang
-
Publication number: 20100256227Abstract: The present invention concerns the uses of an azaphilone compound of formula (I): formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification for modulation of the activity of a nuclear hormone receptor and for prevention and/or treatment of a disease or disorder related to nuclear hormone receptor activity.Type: ApplicationFiled: April 5, 2010Publication date: October 7, 2010Inventors: Ta-Wei D. LIU, Yen-Lin Chen, Ming-Der Wu, Ming-Jen Cheng, Hui-Ping Chen, Wen-Jung Wu, Kai-Ping Chen, Yu-Shan Lin, Gwo-Fang Yuan
-
Publication number: 20100256072Abstract: The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph?-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.Type: ApplicationFiled: March 24, 2006Publication date: October 7, 2010Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Danilo Perrotti, Paolo Neviani, Ramasamy Santhanam, John C. Byrd, Guido Marcucci, Natarajan Muthusamy, Ching-Shih Chen
-
Publication number: 20100249125Abstract: The present invention describes the selective inhibition of prostaglandin receptors (PGE2), e.g., EP2 and EP4, by one or more inhibitors are selected from 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid and (4Z)-7-[(rel-1S,2S,5R)-5-((1,1?-Biphenyl-4-yl)methoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid and salts thereof as a potential therapeutic tool or to expand the spectrum of currently available treatment options for endometriosis and other chronic gynecological diseases in reproductive age women. PGE2 inhibition through novel cell signaling mechanisms identified by the present invention provides an effective and attractive therapeutic tool for treatment without compromising pregnancy and sex life in the women.Type: ApplicationFiled: March 24, 2010Publication date: September 30, 2010Applicant: THE TEXAS A&M UNIVERSITY SYSTEMInventors: Joe A. Arosh, Sakhila K. Banu
-
Publication number: 20100239562Abstract: A family of potassium channels (Kv) are expressed in neurons when they are damaged. Blockers of these channels protect neurons from several different types of insults, whether due to disease or trauma. Furthermore, blockers of these channels promote neurite outgrowth in neural progenitor cells. These findings permit methods of treating as well as methods for identifying and developing drugs for neurological diseases where injury to neurons may occur.Type: ApplicationFiled: May 22, 2007Publication date: September 23, 2010Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Avindra Nath, Tongguang Wang, Peter Calabresi
-
Publication number: 20100239693Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.Type: ApplicationFiled: January 17, 2007Publication date: September 23, 2010Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Bettina Platt
-
Publication number: 20100233298Abstract: The invention relates to novel cosmetic uses of phytosphingosine or of one of its cosmetically acceptable salts, particularly its hydrochloride, as a slimming agent and/or as an active agent which stimulates the synthesis of leptin by adipocytes, for preparing a cosmetic composition intended for reducing subcutaneous excess fat. The invention also relates to a method of cosmetic treatment intended for obtaining a slimming effect on the human body according to which a cosmetic composition containing phytosphingosine or one of its cosmetically acceptable salts, particularly its hydrochloride, is applied on the parts of the body to be treated. The invention also relates to novel cosmetic compositions containing phytosphingosine or one of its cosmetically acceptable salts, particularly its hydrochloride, in combination with a lipolytic agent selected from the group consisting of CAMP and its derivatives, adenylate cyclase enzyme activating agents and phosphodiesterase enzyme inhibiting agents.Type: ApplicationFiled: May 4, 2010Publication date: September 16, 2010Applicant: LVMH RECHERCHEInventors: Jocelyne FRANCHI, Françoise PELLICIER
-
Publication number: 20100215774Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin and/or other active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: February 8, 2008Publication date: August 26, 2010Inventor: Todd Maibach
-
Publication number: 20100210678Abstract: Provided are non-steroidal tricyclic compounds that are modulators of androgen receptors and methods for making and using such compounds.Type: ApplicationFiled: March 19, 2010Publication date: August 19, 2010Inventors: Lin Zhi, Cornelis Arjan Van Oeveren, Jyun-Hung Chen, Robert I. Higuchi
-
Publication number: 20100203084Abstract: The present invention provides a method for treating pain in a subject in need of treatment, by administering to the subject a non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator, in amounts effective to treat pain in the subject. Also disclosed is a method for treating opioid-withdrawal effects in a subject in need of treatment, by the administration to the subject of a non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator, in amounts effective to treat opioid-withdrawal effects in the subject. Finally, the present invention provides a pharmaceutical composition comprising a non-opioid agent and a selective excitatory-opioid-receptor inactivator, and a pharmaceutically-acceptable carrier.Type: ApplicationFiled: October 12, 2007Publication date: August 12, 2010Inventors: Stanley M. Crain, Ke-Fei Shen
-
Publication number: 20100204186Abstract: Aromatized A-ring derivatives of tetracycline compounds are described.Type: ApplicationFiled: April 22, 2010Publication date: August 12, 2010Applicant: Paratek Pharmaceuticals, Inc.Inventor: Mark L. Nelson
-
Publication number: 20100190752Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicant: Gruenenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke, Thomas Christoph
-
Publication number: 20100184707Abstract: The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation.Type: ApplicationFiled: July 4, 2008Publication date: July 22, 2010Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Serge Picaud, Jose Alain Sahel, Jammoul Firas, Caroline Coriat, Manuel Simonutti
-
Publication number: 20100183751Abstract: Compositions comprising: vasokinetic natural coumarins or extracts containing them; anti-phosphodiesterase agents selected from 3,7-O-di-(2-hydroxyethyl)icaritin or 7-O-hydroxyethyl-icariside II and/or forskolin or extracts containing them; phytoestrogens selected from ferutinine or ferutinine-containing extracts of Ferula sp. or p-pivaloylferutinine.Type: ApplicationFiled: June 26, 2008Publication date: July 22, 2010Applicant: INDENA S.P.A.Inventor: Ezio Bombardelli
-
Publication number: 20100179217Abstract: The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. Compounds of the invention are useful to modulate (e.g. agonize or antagonize) opioid receptor function.Type: ApplicationFiled: November 2, 2007Publication date: July 15, 2010Applicant: University of Iowa Research FoundationInventor: Thomas Prisinzano
-
Publication number: 20100172990Abstract: The biocompatible microgels comprises a polymeric network, said polymeric network comprising monomeric units interconnected with one another through a crosslinking agent, wherein said polymeric network can be obtained by polymerization in a dispersed medium of a biocompatible vinyl monomer and a crosslinking agent. The microgel may further comprise a biologically active agent. Said biocompatible microgels can be used, among other applications, to transport and dose biologically active agents.Type: ApplicationFiled: May 23, 2008Publication date: July 8, 2010Applicant: UNIVERSIDAD DEL PAIS VASCOInventors: Jacqueline Forcada García, Ainara Imaz Makazaga, José Ramos Julián
-
Publication number: 20100166889Abstract: The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: LCS GROUP, LLCInventor: Louis Sanfilippo
-
Publication number: 20100168160Abstract: Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia in a mammal are disclosed.Type: ApplicationFiled: November 19, 2009Publication date: July 1, 2010Applicant: Beth Israel Deaconess Medical Center , Inc. And Trustees of Boston UniversityInventors: Chen-Yu Zhang, Bradford B. Lowell, John A. Porco, JR., Ruichao Shen, Cheng T. Lin, Stefan Krauss
-
Publication number: 20100158829Abstract: The invention is directed to a method and composition suitable for skin color modulation. Particularly, the action of D-dopachrome tautomerase on melanogenesis and/or the transfer of melanin from melanosomes in keratinocytes is reduced, thereby resulting in a change in skin color.Type: ApplicationFiled: December 24, 2008Publication date: June 24, 2010Applicant: Conopco, Inc., d/b/a UNILEVERInventors: John Steven Bajor, Carol Annette Bosko, Jorge Louie CardeNas, Diana Jean Drennan, Diana Marrero, Sheila Alves Rocha, Leonard Shore McGarvey, Margaret McGarvey
-
Patent number: 7741365Abstract: Novel polycyclic cannabinoid analogs are presented which have preferentially high affinities for the cannabinoid CB2 receptor sites.Type: GrantFiled: December 29, 2005Date of Patent: June 22, 2010Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Atmaram Khanolkar
-
Publication number: 20100144855Abstract: The present invention disclosed the application of sedoisoprosan for preparation of medicine for therapy on human HBeAg positive chronic hepatitis B. Results of the clinical trials indicated that sedoisoprosan could effectively inhibit hepatitis B virus, the anti-virus effect is enhanced as the dose is increased and the incidence of adverse events is low. Thus, sedoisoprosan is safe and effective for therapy on human HBeAg positive chronic hepatitis B.Type: ApplicationFiled: August 4, 2009Publication date: June 10, 2010Applicant: GUANGDONG YUELONG PHARMACEUTICAL CO., LTD.Inventors: Qiaolong Zhang, Guoai Zheng, Mingfang Zhang, Manxiang Huang, Chunxu Zuo
-
Patent number: 7728001Abstract: The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. The invention also provides an improved method for isolating intermediate materials useful for obtaining compounds of formula I.Type: GrantFiled: September 12, 2005Date of Patent: June 1, 2010Assignee: University of Iowa Research FoundationInventors: Thomas Prisinzano, Richard Brian Rothman
-
Publication number: 20100122362Abstract: Disclosed are mammalian neuronal cells expressing alpha synuclein as well as methods of screening to identify compounds that decrease toxicity induced by alpha synuclein expression. Compounds identified by such screens can be used to treat or prevent synucleinopathies such as Parkinson's disease, familial Parkinson's disease, Lewy body disease, the Lewy body variant of Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, or the Parkinsonism-dementia complex of Guam.Type: ApplicationFiled: October 12, 2007Publication date: May 13, 2010Applicant: FoldRx Pharmaceuticals, Inc.Inventor: Feng Liang
-
Publication number: 20100119512Abstract: The present invention provides methods for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema.Type: ApplicationFiled: January 25, 2008Publication date: May 13, 2010Applicant: Joslin Diabetes CenterInventors: Edward P. Feener, Lloyd P. Aiello
-
Publication number: 20100113583Abstract: Described are pharmaceutical compositions comprising bupropion, metformin, topiramate, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount of bupropion, metformin, and topiramate. In certain embodiments, an aforementioned method is practiced in conjunction or tandem with a medical procedure or the use of a medical device or both.Type: ApplicationFiled: October 15, 2009Publication date: May 6, 2010Inventor: Louis J. Aronne
-
Publication number: 20100104565Abstract: The present invention relates to combinations of the xanthenone acetic acids class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and EGFR signalling pathway inhibitors. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations.Type: ApplicationFiled: August 25, 2006Publication date: April 29, 2010Inventors: Colin Green, Lloyd Kelland, Sally Kelland, Gail Rowlinson-Brusza
-
Publication number: 20100105764Abstract: There is provided a method for the manufacture of a medicament for the treatment of cancer comprising a compound capable of inhibiting a steroid sulphatase enzyme (E.C.3.1.6.2), wherein the cancer is of a type, in which the cancer cells overexpress aromatase enzyme.Type: ApplicationFiled: June 1, 2009Publication date: April 29, 2010Inventors: Michael John Reed, Atul Purohit, Paul Alexander Foster, Simon Paul Newman, Lok Wai Lawrence Woo, Barry Victor Lloyd Potter, Gillian Reed
-
Publication number: 20100105765Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: ApplicationFiled: January 6, 2010Publication date: April 29, 2010Inventor: Thomas Najarian
-
Patent number: 7705039Abstract: A method of ameliorating a sleep-related breathing disorder via administration of at least one cannabimimetic agent, such as oleamide or ?9THC, to an individual in need of treatment.Type: GrantFiled: April 8, 2002Date of Patent: April 27, 2010Assignee: The Board of Trustees of the University of IllinoisInventors: David W. Carley, Miodrag Radulovacki
-
Patent number: 7705040Abstract: This invention provides compositions which specifically reacts with peroxynitrite rather than other reactive oxygen species and reactive nitrogen species. This invention also provides related agents for measuring peroxynitrite. This invention also provides related methods for measuring peroxynitrite in a sample, high-throughput screening fluorescent methods for detecting peroxynitrite and high-throughput methods for screening compounds that increase or decrease the production of peroxynitrite comprising using such compositions and agents.Type: GrantFiled: October 7, 2005Date of Patent: April 27, 2010Assignee: The University of Hong KongInventors: Dan Yang, Hua-Li Wang, Zhen-Ning Sun, Jian-Gang Shen
-
Publication number: 20100099754Abstract: A method of preparation of 5,6-dimethylxanthone-4-acetic acid (DMXAA) and derivatives thereof. The derivatives are represented by formula (I), wherein R represents totally 1 to 2 substitutes at 1, 2, 3, 7, and 8 position selected from a lower alkyl, halogen, CF3, CN, NO2, NH2, CH2COOH, OR2, OH, NHSO2R2, SR2, CH2CONHR2 or NHR2, and R2 represents a lower alkyl, or a lower alkyl having OH, NH2, or OCH3. The invention further provides a pharmaceutical composition having such derivatives used as excellent antitumor and antibacterial agents.Type: ApplicationFiled: October 19, 2009Publication date: April 22, 2010Inventors: Wei LI, Guofan XIE, Jianzhong ZHOU, Bo YANG, Zhiqiang QIAN, Yan CHEN, Haiming GENG, Jianming ZHOU, Lu HUANG